Cost burden of viral respiratory infections: issues for formulary decision makers (Q34602681)

3 August 2017

1 reference

title

Cost burden of viral respiratory infections: issues for formulary decision makers (English)

1 reference

3 August 2017

Joseph S Bertino

1

1 reference

PubMed ID

11955459

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

American Journal of Medicine

3 August 2017

1 reference

3 August 2017

112 Suppl 6A

1 reference

3 August 2017

42S-49S

1 reference

The family physician's reasonable approach to upper respiratory tract infection care for this century

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Measurements of the Prevalence of Viral Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Frequency and severity of infections in day care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Excessive antibiotic use for acute respiratory infections in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Interethnic differences of drug-metabolizing enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Acute liver failure; clinical features and management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

A controlled study of the effect of oral penicillin G in the treatment of non-specific upper respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Antibiotics and chemotherapeutic agents in the treatment of uncomplicated respiratory infections in children; a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Evaluation of orally administered antibiotics for treatment of upper respiratory infections in Thai children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Randomised controlled trial of antibiotics in patients with cough and purulent sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Amoxycillin and co-trimoxazole in presumed viral respiratory infections of childhood: placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Systematic review of the treatment of upper respiratory tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

The responsibility of the infectious disease community for the optimal use of antimicrobial agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Antimicrobial prescribing for acute purulent rhinitis in children: a survey of pediatricians and family practitioners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Antibiotic prescribing for patients with colds, upper respiratory tract infections, and bronchitis: A national study of hospital-based emergency departments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

The crisis in antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Current attitudes regarding use of antimicrobial agents: results from physician's and parents' focus group discussions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Antibiotics prescription in primary care: a 5-year follow-up of an educational programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

Bacteriology and treatment of purulent nasopharyngitis: a double blind, placebo-controlled evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Health and economic impacts of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901063-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)01063-4

1 reference

3 August 2017

1 reference

PubMed ID

11955459